Evolution of humoral lesions on follow-up biopsy stratifies the risk for renal graft loss after antibody-mediated rejection treatment.
Antonin BouchetBrieuc MullerJerome OlagneThomas BarbaMélanie JolyAugustin ObrechtMaud RabeyrinFrédérique DijoudCécile PicardSarah MezaacheAntoine SicardAlice KoenigAnne ParissiadisValérie DuboisEmmanuel MorelonSophie CaillardOlivier ThaunatPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022)
We conclude that invasive monitoring of the evolution of humoral lesions by the mean of follow-up biopsy performed 3-6 months after the initiation of therapy is an interesting tool to predict long-term outcome after AMR treatment.